tradingkey.logo

OmniAb Inc

OABIW

0.150USD

0.000
Cierre 09/19, 16:00ETCotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de OmniAb Inc Compañía
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Información de la empresa
Símbolo de cotizaciónOABIW
Nombre de la empresaOmniAb Inc
Fecha de salida a bolsaOct 09, 2020
Director ejecutivoMr. Matthew William (Matt) Foehr
Número de empleados- -
Tipo de seguridadCompany Warrant
Fin del año fiscal- -
Dirección5980 Horton Street
CiudadEMERYVILLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94608
Teléfono15102507800
Sitio Webhttps://www.omniab.com/
Símbolo de cotizaciónOABIW
Fecha de salida a bolsaOct 09, 2020
Director ejecutivoMr. Matthew William (Matt) Foehr
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Otro
100.00%
Accionistas
Accionistas
Proporción
Otro
100.00%
Tipos de accionistas
Accionistas
Proporción
Otro
100.00%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
27
14.22M
0.00%
-4.38M
2025Q1
30
14.22M
0.00%
-4.87M
2024Q4
31
14.27M
0.00%
-4.01M
2024Q3
40
15.02M
0.00%
-4.74M
2024Q2
44
16.42M
0.00%
-4.17M
2024Q1
44
16.68M
0.00%
-3.92M
2023Q4
44
16.86M
0.00%
+8.02M
2023Q3
42
5.61M
0.00%
-2.94M
2023Q2
41
5.80M
0.00%
-2.20M
2023Q1
39
5.66M
0.00%
-2.25M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Walleye Trading, LLC
--
0%
-22.51K
-100.00%
Dec 31, 2024
Susquehanna International Group, LLP
--
0%
-16.35K
-100.00%
Mar 31, 2024
Avista Capital Holdings, LP
11.35M
0%
--
--
Sep 30, 2024
LMR Partners LLP
897.39K
0%
--
--
Mar 31, 2025
Aristeia Capital, L.L.C.
692.92K
0%
--
--
Mar 31, 2025
Hudson Bay Capital Management LP
465.23K
0%
-2.75K
-0.59%
Mar 31, 2025
Sculptor Capital Management, Inc
339.40K
0%
--
--
Mar 31, 2025
Calamos Advisors LLC
200.00K
0%
--
--
Mar 31, 2025
MMCAP Asset Management
158.33K
0%
--
--
Mar 31, 2025
Wolverine Asset Management, LLC
1.55K
0%
-70.33K
-97.85%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI